Edward Nirenberg on Nostr: In terms of implementation... there were hiccups. The recommendation for nirsevimab ...
In terms of implementation... there were hiccups. The recommendation for nirsevimab ended up being a lot broader than Sanofi, the manufacturer, was prepared to accommodate. Hence accessing nirsevimab was really tough. There were also issues with cost and reimbursement.
Published at
2024-06-28 14:49:00Event JSON
{
"id": "0584a28f87dab19cfcb930025286b45f7fb28005e495e0cb20866dd3d4c072c9",
"pubkey": "c67b38e4c5023e985f04ae7ab6a6669cf463220e1b9ed54b897d1957004603a4",
"created_at": 1719586140,
"kind": 1,
"tags": [
[
"e",
"3f7693987c50d51d28246f5fcf61e87c38a4449be978b01e5c1dbbb562c33222",
"wss://relay.mostr.pub",
"reply"
],
[
"proxy",
"https://med-mastodon.com/users/enirenberg/statuses/112694797318716508",
"activitypub"
]
],
"content": "In terms of implementation... there were hiccups. The recommendation for nirsevimab ended up being a lot broader than Sanofi, the manufacturer, was prepared to accommodate. Hence accessing nirsevimab was really tough. There were also issues with cost and reimbursement.\n\nhttps://cdn.masto.host/medmastodoncom/media_attachments/files/112/694/797/246/946/836/original/17f017a7d96e2b13.png",
"sig": "518a1400d5f11e0be06b6d7df56f56be14e09329733ff9b2da16011da0646e06d73569229c528fa6e3ecc79a89075f8698e0040e0d5d65e4be3383b7135846d0"
}
